96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.

MLA

Malan, D. R.Niel, et al. “96-Week Efficacy and Safety of Atazanavir, with and without Ritonavir, in a HAART Regimen in Treatment-Naive Patients.” Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), vol. 9, no. 1, Jan. 2010, pp. 34–42. EBSCOhost, https://doi.org/10.1177/1545109709355828.

APA

Malan, D. R. N., Krantz, E., David, N., Rong Yang, Mathew, M., Iloeje, U. H., Jun Su, & McGrath, D. (2010). 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 9(1), 34–42. https://doi.org/10.1177/1545109709355828

Chicago

Malan, D R Niel, Edrich Krantz, Neal David, Rong Yang, Marina Mathew, Uchenna H Iloeje, Jun Su, and Donnie McGrath. 2010. “96-Week Efficacy and Safety of Atazanavir, with and without Ritonavir, in a HAART Regimen in Treatment-Naive Patients.” Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 9 (1): 34–42. doi:10.1177/1545109709355828.